I-Corps: diagnostic & patient management tool for physicians treating movement disorders
I军团:诊断
基本信息
- 批准号:2330751
- 负责人:
- 金额:$ 5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:Standard Grant
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The broader impact/commercial potential of this I-Corps project is to accelerate the drug development process for neuropsychiatric compounds and improve the clinical management of brain disorders. This project will evaluate whether advances in deep learning-based pose tracking algorithms can lead to new business opportunities within both biotech/pharma and healthcare. Behavior is a result of the complex coordination of brain processes and is affected by disease or impairment. The behavioral repertoire of a patient or animal is a rich noninvasive source of data about its neuropsychiatric health, but limited tools exist to mine this type of data. Solving the problem of behavioral quantification has the potential to make neuropsychiatric drug development more efficient by providing biotech/pharma with a better understanding of how their drugs are working from the time they are first tested in animals all the way through pivotal human studies. Behavioral quantification tools can also assist clinicians with the treatment of neuropsychiatric diseases, which due to their complexity typically require extensive training to properly diagnose and manage. This I-Corps project is based on the development of a deep learning based behavioral quantification tool for use in drug development and clinical medicine. Current approaches to measure the efficacy of neuropsychiatric interventions are limited by their sensitivity, efficiency, and reproducibility. Breakthroughs in neuroscience have elucidated new mechanisms for drug developers to target, but limited techniques exist to evaluate the efficacy of new treatments. In addition, animal models for neuropsychiatric testing have limited translatability to clinical results, making asset prioritization difficult for drug developers. Deep learning based behavioral measurement tools serve as a noninvasive solution to this problem by automating behavioral analysis with high sensitivity and specificity. These tools can extract insights that are currently inaccessible to drug developers, which will not only lead to advances in the understanding of the biology of disease, but also the collection of pivotal data for drug approval. The ability of biotech/pharma to robustly characterize therapeutic efficacy across all stages of development reduces the regulatory and commercial risks currently associated with neuropsychiatric drug development. Similarly, physicians would be able to use advanced behavioral quantification techniques to compare a patient’s symptoms against a library of “digital fingerprints” to accurately diagnose conditions and manage symptoms.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
I-Corps项目更广泛的影响/商业潜力是加速神经精神化合物的药物开发过程,改善脑部疾病的临床管理。该项目将评估基于深度学习的姿态跟踪算法的进步是否可以在生物技术/制药和医疗保健领域带来新的商业机会。行为是大脑过程复杂协调的结果,并受到疾病或损伤的影响。病人或动物的行为特征是有关其神经精神健康的丰富的非侵入性数据来源,但目前用于挖掘这类数据的工具有限。解决行为量化的问题有可能使神经精神药物的开发更有效,因为它使生物技术/制药公司更好地了解他们的药物从第一次在动物身上测试到关键的人类研究是如何起作用的。行为量化工具还可以帮助临床医生治疗神经精神疾病,由于其复杂性,通常需要广泛的培训才能正确诊断和管理。这个I-Corps项目的基础是开发一种基于深度学习的行为量化工具,用于药物开发和临床医学。目前测量神经精神干预效果的方法受到其敏感性、效率和可重复性的限制。神经科学的突破已经阐明了药物开发人员可以瞄准的新机制,但目前评估新疗法疗效的技术有限。此外,用于神经精神测试的动物模型对临床结果的可翻译性有限,这使得药物开发人员难以确定资产的优先级。基于深度学习的行为测量工具通过高灵敏度和特异性的自动化行为分析,为解决这一问题提供了一种无创解决方案。这些工具可以提取药物开发人员目前无法获得的见解,这不仅将导致对疾病生物学的理解取得进展,而且还将收集药物批准的关键数据。生物技术/制药在所有开发阶段都能强有力地描述治疗效果的能力,降低了目前与神经精神药物开发相关的监管和商业风险。同样,医生将能够使用先进的行为量化技术将患者的症状与“数字指纹”库进行比较,以准确诊断病情并管理症状。该奖项反映了美国国家科学基金会的法定使命,并通过使用基金会的知识价值和更广泛的影响审查标准进行评估,被认为值得支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Timothy Dunn其他文献
Lower urinary tract obstruction: fetal intervention based on prenatal staging
- DOI:
10.1007/s00467-017-3593-8 - 发表时间:
2017-07-21 - 期刊:
- 影响因子:2.600
- 作者:
Rodrigo Ruano;Timothy Dunn;Michael C. Braun;Joseph R. Angelo;Adnan Safdar - 通讯作者:
Adnan Safdar
SPERM CRYOPRESERVATION IS ASSOCIATED WITH AN INCREASED INCIDENCE OF ABNORMALLY-FERTILIZED EMBRYOS IN emIN VITRO/em FERTILIZATION CYCLES (IVF) USING INTRA-CYTOPLASMIC SPERM INJECTION (ICSI)
精子冷冻保存与使用胞浆内精子注射(ICSI)的体外受精(IVF)周期中异常受精胚胎发生率的增加有关。
- DOI:
10.1016/j.fertnstert.2023.08.073 - 发表时间:
2023-10-01 - 期刊:
- 影响因子:7.000
- 作者:
Alvin To;Timothy Dunn;Anna Claire Reynolds;Jean-Claire Dillon;Laurie McKenzie;Laura Detti - 通讯作者:
Laura Detti
Predictors of the timing of interval cytoreduction based on the number of cycles of neoadjuvant chemotherapy: a retrospective cohort
- DOI:
10.1016/s0090-8258(21)01111-2 - 发表时间:
2021-08-01 - 期刊:
- 影响因子:
- 作者:
Timothy Dunn;Sara Norton;T. Miller Sisson;Gerald McGwin;Haller Smith - 通讯作者:
Haller Smith
PREIMPLANTATION GENETIC TESTING AND PLACENTAL ABNORMALITIES: A SYSTEMATIC REVIEW AND META-ANALYSIS
- DOI:
10.1016/j.fertnstert.2023.08.108 - 发表时间:
2023-10-01 - 期刊:
- 影响因子:
- 作者:
Isaac J. Chamani;Lauren L. Taylor;Timothy Dunn;Anna Claire Reynolds;Beatriz Varman;Karin Anneliese Fox;Laura Detti - 通讯作者:
Laura Detti
SPERM CRYOPRESERVATION IS ASSOCIATED WITH AN INCREASED INCIDENCE OF ABNORMALLY-FERTILIZED EMBRYOS IN <em>IN VITRO</em> FERTILIZATION CYCLES (IVF) USING INTRA-CYTOPLASMIC SPERM INJECTION (ICSI)
- DOI:
10.1016/j.fertnstert.2023.08.073 - 发表时间:
2023-10-01 - 期刊:
- 影响因子:
- 作者:
Alvin To;Timothy Dunn;Anna Claire Reynolds;Jean-Claire Dillon;Laurie McKenzie;Laura Detti - 通讯作者:
Laura Detti
Timothy Dunn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
- 批准号:82372328
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
HER2特异性双抗原表位识别诊疗一体化探针研制与临床前诊疗效能研究
- 批准号:82372014
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
相似海外基金
Cyclic di-AMP-dependent signaling in tickborne relapsing fever Borrelia
蜱传回归热伯氏疏螺旋体中的环状双 AMP 依赖性信号传导
- 批准号:
10679004 - 财政年份:2022
- 资助金额:
$ 5万 - 项目类别:
Role of AMP-kinase pathway in the regulation of Minimal change disease-to-FSGS transition
AMP-激酶途径在微小病变向 FSGS 转变调节中的作用
- 批准号:
10585051 - 财政年份:2022
- 资助金额:
$ 5万 - 项目类别:
Cyclic di-AMP-dependent signaling in tickborne relapsing fever Borrelia
蜱传回归热伯氏疏螺旋体中的环状双 AMP 依赖性信号传导
- 批准号:
10503309 - 财政年份:2022
- 资助金额:
$ 5万 - 项目类别:
AMP-AD Brain Proteomic Network Enhancement, Validation, and Translation into CSF Biomarkers
AMP-AD 脑蛋白质组网络增强、验证并转化为 CSF 生物标志物
- 批准号:
10013105 - 财政年份:2018
- 资助金额:
$ 5万 - 项目类别:
Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF Biomarkers
AMP-AD 脑蛋白质组网络的补充,增强、验证并转化为 CSF 生物标志物
- 批准号:
10406764 - 财政年份:2018
- 资助金额:
$ 5万 - 项目类别:
Data Coordination for the AMP Autoimmune and Related (AR) Knowledge Portal
AMP 自身免疫及相关 (AR) 知识门户的数据协调
- 批准号:
10374660 - 财政年份:2018
- 资助金额:
$ 5万 - 项目类别:
AMP-AD Brain Proteomic Network Enhancement, Validation, and Translation into CSF Biomarkers
AMP-AD 脑蛋白质组网络增强、验证并转化为 CSF 生物标志物
- 批准号:
10474124 - 财政年份:2018
- 资助金额:
$ 5万 - 项目类别:
AMP-AD Brain Proteomic Network Enhancement, Validation, and Translation into CSF Biomarkers
AMP-AD 脑蛋白质组网络增强、验证并转化为 CSF 生物标志物
- 批准号:
9788998 - 财政年份:2018
- 资助金额:
$ 5万 - 项目类别:
AMP-AD Brain Proteomic Network Enhancement, Validation, and Translation into CSF Biomarkers
AMP-AD 脑蛋白质组网络增强、验证并转化为 CSF 生物标志物
- 批准号:
10475094 - 财政年份:2018
- 资助金额:
$ 5万 - 项目类别: